ADXS-HPV Designated Orphan Drug for HPV-Related Head & Neck Cancer

Share this content:

Advaxis announced that the FDA has granted ADXS-HPV Orphan Drug Designation for the treatment of human papillomavirus (HPV)-associated head and neck cancer.

Related: Head and Neck Cancer Resource Center

ADXS-HPV is an immunotherapy designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy.

Previously the FDA granted ADXS-HPV Orphan Drug Designation for the treatment of human papillomavirus (HPV)-associated anal cancer.

ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer, locally advanced cervical cancer, head & neck cancer, and anal cancer.

For more information call (609) 452-9813 or visit Advaxis.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs